Used in research and therapeutic development for immune modulation, particularly in oncology and autoimmune diseases. Targets BST2 (CD317), a protein involved in restricting viral release and regulating B-cell activation. Enables selective depletion of pathogenic B-cells by engaging immune effector cells through Fc-mediated mechanisms. Investigated for potential in treating B-cell malignancies and chronic inflammatory conditions by modulating immune signaling pathways. Also serves as a reference standard in antibody engineering and biosimilar development due to its well-characterized binding and functional properties.